Fig. 7
Anti-tumor effect of AbPD−L1/CD24-mPDA@CuO2 NRs in vivo. (A) Treatment protocols assessing H2O2 self-supplying CDT + CBIT by intratumoral injection of dAbPD−L1/CD24-mPDA@CuO2 NRs. (B) Time-dependent tumor growth curves in 4T1 tumor-bearing mice after various treatments with intratumoral injections. The values are expressed as means ± SD (n = 8). Asterisks indicate a significant difference between the AbPD−L1/CD24-mPDA@CuO2 NRs treated group and the AbPD−L1/CD24-mPDA NPs and mPDA@CuO2 NRs treated groups (Student’s t-test, *p ≤ 0.05). (C) Body weight of 4T1 tumor-bearing mice in different groups after treatments. The values are expressed as means ± SD (n = 8). (D) Protein expression level of IFN-γ in tumor tissues after treatment to block the PD-L1–PD1 signaling between cancer cells and T cells using AbPD−L1/CD24-mPDA@CuO2 NRs (the bottom inset shows a corresponding digital photo of immunohistochemistry). The values are expressed as means ± SD (n = 3). Asterisks indicate a significant difference (Student’s t-test, *p ≤ 0.05). Scale bar = 200 μm. (E) Immunohistochemical analysis of immune responses, focusing on CD68 (infiltrating macrophages) in tumor tissues from mice treated with mPDA@CuO2 NRs and dAbPD−L1/CD24-mPDA@CuO2 NRs. Scale bar = 500 μm